OPKO Health (OPK) Competitors

OPKO Health (NASDAQ:OPK) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, community ranking, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Do analysts recommend OPK or BCRX?

OPKO Health currently has a consensus price target of $2.75, indicating a potential upside of 112.36%. BioCryst Pharmaceuticals has a consensus price target of $16.56, indicating a potential upside of 68.76%. Given OPKO Health's higher probable upside, analysts plainly believe OPKO Health is more favorable than BioCryst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OPKO Health	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
BioCryst Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89

Do institutionals & insiders believe in OPK or BCRX?

64.6% of OPKO Health shares are owned by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 49.7% of OPKO Health shares are owned by insiders. Comparatively, 4.8% of BioCryst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Which has more volatility & risk, OPK or BCRX?

OPKO Health has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500.

Which has preferable earnings and valuation, OPK or BCRX?

OPKO Health has higher revenue and earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than OPKO Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OPKO Health	$689.41M	1.49	-$188.86M	-$0.07	-18.50
BioCryst Pharmaceuticals	$503.49M	4.08	-$226.54M	-$0.26	-37.73

Does the MarketBeat Community prefer OPK or BCRX?

OPKO Health received 16 more outperform votes than BioCryst Pharmaceuticals when rated by MarketBeat users. However, 67.07% of users gave BioCryst Pharmaceuticals an outperform vote while only 65.60% of users gave OPKO Health an outperform vote.

Company	Underperform	Outperform
OPKO Health	Outperform Votes 513 65.60%	Underperform Votes 269 34.40%
BioCryst Pharmaceuticals	Outperform Votes 497 67.07%	Underperform Votes 244 32.93%

Is OPK or BCRX more profitable?

OPKO Health has a net margin of -18.65% compared to BioCryst Pharmaceuticals' net margin of -30.01%. BioCryst Pharmaceuticals' return on equity of 0.00% beat OPKO Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OPKO Health	-18.65%	-9.76%	-6.46%
BioCryst Pharmaceuticals	-30.01%	N/A	-24.06%

Does the media refer more to OPK or BCRX?

In the previous week, BioCryst Pharmaceuticals had 42 more articles in the media than OPKO Health. MarketBeat recorded 44 mentions for BioCryst Pharmaceuticals and 2 mentions for OPKO Health. BioCryst Pharmaceuticals' average media sentiment score of 1.00 beat OPKO Health's score of 0.68 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OPKO Health	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioCryst Pharmaceuticals	16 Very Positive mention(s)	6 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

OPKO Health beats BioCryst Pharmaceuticals on 10 of the 18 factors compared between the two stocks.